Cephalexin Dosing for Acute Paronychia
For an otherwise healthy adult with acute paronychia, prescribe cephalexin 500 mg orally four times daily for 7 days, though twice-daily dosing (500 mg BID) is an acceptable alternative that may improve adherence.
Dosing Recommendations
Standard Regimen
- Dose: 500 mg orally four times daily (QID)
- Duration: 7 days
- Rationale: The FDA label indicates that for skin and skin structure infections, 500 mg every 12 hours may be used, but the standard adult dose is 250 mg every 6 hours, with 500 mg doses appropriate for infections 1. The IDSA guidelines support cephalexin 500 mg QID for MSSA skin and soft tissue infections 2.
Alternative Simplified Regimen
- Dose: 500 mg orally twice daily (BID)
- Duration: 7 days
- Rationale: Multiple studies demonstrate that twice-daily cephalexin is equally effective as four-times-daily dosing for skin and soft tissue infections, with cure rates exceeding 97% 3, 4. This simplified regimen may enhance patient compliance while maintaining therapeutic efficacy.
Clinical Context for Paronychia
Acute paronychia is a polymicrobial infection occurring after breach of the protective nail barrier 5. The treatment approach depends on severity:
When Antibiotics Are Indicated
- Presence of cellulitis extending beyond the nail fold
- Systemic signs of infection (fever, lymphangitis)
- Failed conservative management (warm soaks, drainage if abscess present)
- Immunocompromised patients
Important Caveat
Oral antibiotics are usually not needed if adequate drainage of an abscess is achieved, unless the patient is immunocompromised or has severe infection 5. Simple paronychia with localized abscess should be drained first, with antibiotics reserved for surrounding cellulitis or treatment failures.
Pathogen Coverage
Cephalexin provides excellent coverage for the typical pathogens in acute paronychia:
- Staphylococcus aureus (methicillin-susceptible strains)
- Streptococcus pyogenes
The IDSA guidelines list cephalexin as an appropriate oral agent for MSSA skin and soft tissue infections, with dosing of 25-50 mg/kg/day in 4 divided doses (or 500 mg QID in adults) 2.
Practical Considerations
Dosing Frequency Trade-offs
- QID dosing: More established in guidelines, maintains more consistent drug levels
- BID dosing: Improved adherence, equally effective based on clinical trials 3, 4, FDA-approved for skin infections 1
When to Escalate Therapy
Consider MRSA coverage (trimethoprim-sulfamethoxazole, doxycycline, or clindamycin) if:
- Initial treatment failure at 48-72 hours
- Known MRSA colonization or previous MRSA infection
- Severe infection with systemic symptoms
- Local MRSA prevalence is high
Duration Rationale
Seven days is the standard duration for uncomplicated skin and soft tissue infections 1. Shorter courses may be inadequate, while longer courses are unnecessary for simple paronychia with appropriate drainage.